Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

with levels increasing after discontinuing sargramostim a GM-CSF = granulocyte-macrophage colony-stimulating factor; BCG = bacillus Calmette-Guérin vaccine; RR = response rate, including complete ...

Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with ...

A dietary change that included a decrease in dietary omega-6 and an increase in omega-3 fatty acids could reduce prostate ...

The four colony-stimulating factors (CSFs) are glycoproteins that ... Recombinant granulocyte-CSF (G-CSF) and granulocyte–macrophage-CSF (GM-CSF) have now been used to increase dangerously ...

This is the first regulatory approval of an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) product for this indication. In Japan, Leukine is branded as Sargmalin and ...

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

Molgramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), is designed to stimulate alveolar macrophages to clear surfactant effectively. Savara's forward-looking ...

The intervention group showed reduced triglyceride levels and macrophage colony-stimulating factor, with no change in tumor volume or PSA. Further studies, including phase 3 and longer-term trials, ...

with levels increasing after discontinuing sargramostim a GM-CSF = granulocyte-macrophage colony-stimulating factor; BCG = bacillus Calmette-Guérin vaccine; RR = response rate, including complete ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...